United Therapeutics Corp’s filing revealed that its EVP & GENERAL COUNSEL MAHON PAUL A unloaded Company’s shares for reported $3.35 million on Jul 24 ’25. In the deal valued at $304.11 per share,11,000 shares were sold. As a result of this transaction, MAHON PAUL A now holds 36,781 shares worth roughly $10.76 million.
Then, PAUL MAHON bought 11,000 shares, generating $3,345,224 in total proceeds.
Before that, MAHON PAUL A sold 11,000 shares. United Therapeutics Corp shares valued at $3,303,394 were divested by the EVP & GENERAL COUNSEL at a price of $300.31 per share. As a result of the transaction, MAHON PAUL A now holds 36,781 shares, worth roughly $10.76 million.
Cantor Fitzgerald initiated its United Therapeutics Corp [UTHR] rating to an Overweight in a research note published on June 02, 2025; the price target was $405. A number of analysts have revised their coverage, including Wells Fargo’s analysts, who decreased its forecast for the stock in late April from “an Overweight” to “an Equal weight”. BofA Securities also remained covering UTHR and has increased its forecast on April 21, 2025 with a “Neutral” recommendation from previously “an Underperform” rating. Morgan Stanley revised its rating on July 11, 2024. It rated UTHR as “an Equal-weight” which previously was an “an Overweight”.
Price Performance Review of UTHR
On Monday, United Therapeutics Corp [NASDAQ:UTHR] saw its stock fall -0.55% to $292.65. Over the last five days, the stock has lost -1.84%. United Therapeutics Corp shares have fallen nearly -6.59% since the year began. Nevertheless, the stocks have fallen -17.06% over the past one year.
How much short interest is there in United Therapeutics Corp?
A steep rise in short interest was recorded in United Therapeutics Corp stocks on 2025-07-15, dropping by 14390.0 shares to a total of 1.6 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 1.61 million shares. There was a decline of -0.9%, which implies that there is a negative sentiment for the stock.
